Gastric Carcinoma Clinical Trial
Official title:
A Registry Study on Shenqifuzheng(a Chinese Medicine Injection)Used in Hospitals in China
This study was advocated by Institute of Basic Research in Clinical Medicine, China Academy
of Chinese Medical Sciences in December 2012.
It was funded by China major scientific and technological specialized project for
'significant new formulation of new drugs'.
The purpose of this study is to make a cohort event monitoring to see whether and how
Shenqifuzheng injection in hospital results in adverse events or adverse drug reactions.
It is very common that Chinese Medicine Injection used in hospitals in mainland China.
However safety problems rose in recent years. There could be many uncertain factors influence
Chinese Medicine Injection in clinical practice.
Safety surveillance on Chinese Medicine injection is an important problem that needs to be
sorted out through large sample observational study.
A registry study for Shenqifuzheng injection safety surveillance with 30000 patients will be
conducted from Jan.2013 to Dec.2014.
Eligibility criteria Patients who will use Shenqifuzheng injection in selected hospitals
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04602026 -
The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer
|
N/A | |
Not yet recruiting |
NCT03599778 -
XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT00256321 -
Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma
|
Phase 2 | |
Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
Recruiting |
NCT02617134 -
CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
|
Phase 1/Phase 2 | |
Recruiting |
NCT02317471 -
Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03735511 -
A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
|
||
Recruiting |
NCT04410302 -
Patient-Derived Xenografts to Reduce Cancer Health Disparities
|
||
Recruiting |
NCT05596188 -
Anxiety Before Non-cardiac Surgery in Adults
|
||
Recruiting |
NCT02611024 -
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT04254107 -
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT01348009 -
Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT00639522 -
Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma
|
Phase 1 | |
Recruiting |
NCT05811546 -
Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma
|
||
Recruiting |
NCT05229809 -
Clinical Trial of Yiqi Wenyang Jiedu Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Gastric Cancer
|
Phase 4 | |
Recruiting |
NCT02409199 -
A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00970138 -
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT06408220 -
Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer
|
N/A | |
Recruiting |
NCT04443036 -
Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma
|
N/A | |
Active, not recruiting |
NCT04505553 -
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
|
Phase 2 |